Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Ross Stores, Inc. (ROST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Ross Stores, Inc. — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $299.54 (market cap $8.04B), while Ross Stores, Inc. trades at $225.56 (market cap $70.87B). The key difference: Ross Stores, Inc. is far larger — about 8.8× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Ross Stores, Inc. pays a 0.81% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | ROST | |
|---|---|---|
Market Cap | $8.04B | $70.87B |
Sector | Health | Consumer Cyclical |
52-Week High | $339.75 | $240.13 |
52-Week Low | $241.71 | $127.59 |
Enterprise Value | $7.85B | $71.46B |
Dividend Yield | — | 0.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
Ross Stores (ROST) trades at $219.46, down 1.53% on the day, with a bullish technical outlook supported by moving averages and consistent earnings beats. The company demonstrates strong profitability with a 9.74% net margin and 38.98% ROE, while revenue grew to $21.13B in 2025. Recent news highlights robust Q1 2026 performance with 21% sales growth and expanding margins.
The stock offers upside to the $259 consensus price target, driven by operational efficiency and store expansion. Risks include consumer spending sensitivity and competitive pressures. Analyst sentiment is strongly positive with 64% buy ratings, though valuation multiples like the 30.65 P/E warrant monitoring amid market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Ross Stores, Inc.
Ross Stores is a leading American off-price apparel and home fashion retailer, operating over 1,920 stores (at the end of fiscal 2021) across the Ross Dress for Less and dd's Discounts banners. Ross offers a variety of name-brand products and targets undercutting conventional retailers' regular prices by 20%-70%. The company uses an opportunistic, flexible merchandising approach
Read more on ROST →
